Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants (LPD)
This randomised, placebo-controlled, triple-blind Phase I crossover trial (n=24) will compare the acute and subacute effects of LSD (150µg), psilocybin (30mg), and DMT (up to 2 mg/min intravenous infusion) in healthy adults, with all sessions standardised using ketanserin (20 mg IV) to end the psychedelic experience after three hours.
Details
The LPD study is a 4-period randomized crossover in healthy volunteers to compare moderately high doses of LSD (150 µg), psilocybin (30 mg) and an IV DMT infusion (modeled to match oral kinetics) while standardising experience duration using 20 mg IV ketanserin at three hours.
Primary aims are basic science: to assess whether equivalent peak subjective effects occur across compounds when duration is fixed; outcomes include acute and subacute subjective measures and pharmacokinetic/pharmacodynamic characterisation.